Ravindra Majeti, MD
Hematology · Stanford
- Medicare standing
- 2 flags on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
- California licence: Delinquent
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Majeti’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A86286 · Delinquent
Licence status: Delinquent · since 2004 · expires 2025-08-31 · University of California San Francisco School of Medicine.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$7,370 in 2025
| 2025 | 1 | 2 | $7,370 | $7,370 |
| 2024 | 1 | 1 | None | $147 |
| 2022 | 2 | 5 | $11,237 | $13,083 |
| 2021 | 1 | 3 | $22,500 | $22,500 |
| 2020 | 1 | 2 | $15,000 | $15,000 |
| 2019 | 2 | 2 | None | $88 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | None | $7,370 | 2 payments
|
See all 2 published payments
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-12-31 | None | $5,000 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-11-25 | None | $2,370 |
See earlier years (2024, 2022, 2021, 2020, 2019)
2024: $147
| Astellas Pharma US | Xospata | $147 | 1 payment
|
2022: $13,083
| Coherus Biosciences | None | $7,500 | 1 payment
|
| F. Hoffmann-La Roche AG | None | $5,583 | 4 payments
|
2021: $22,500
| Coherus Biosciences | None | $22,500 | 3 payments
|
2020: $15,000
| Coherus Biosciences | None | $15,000 | 2 payments
|
2019: $88
| Astellas Pharma US | Xospata | $75 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | None | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Gilead Sciences, Inc. · Therapeutic Targeting of Aml/Mds With Magrolimab · 2021 | Their institution | $460,749 |
| Gilead Sciences, Inc. · Therapeutic Targeting of Aml/Mds With Magrolimab · 2024 | Their institution | $247,716 |
Professional record
- NPI
- 1326195447
- Licence
- CA A86286California A86286: Delinquent · expires 2025-08-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-01-03
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 875 Blake Wilbur Dr, Palo Alto, CA, 94304